Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Eterna Therapeutics Inc (ERNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ERNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.85% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.62M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 7.12 | 52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 |
52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2652.9% |
Management Effectiveness
Return on Assets (TTM) -32.42% | Return on Equity (TTM) -2264.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14647264 | Price to Sales(TTM) 25.45 |
Enterprise Value 14647264 | Price to Sales(TTM) 25.45 | ||
Enterprise Value to Revenue 27.38 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 7361200 | Shares Floating 1664157 |
Shares Outstanding 7361200 | Shares Floating 1664157 | ||
Percent Insiders 61.04 | Percent Institutions 1.35 |
Upturn AI SWOT
Eterna Therapeutics Inc
Company Overview
History and Background
Eterna Therapeutics Inc. is a biotechnology company focused on developing mRNA-based medicines. Founded in 2015, it has advanced multiple preclinical programs, focusing on oncology and inflammatory diseases. Milestones include securing venture funding and advancing pipeline candidates into clinical development.
Core Business Areas
- mRNA Therapeutics: Development of messenger RNA (mRNA) based therapeutics for a range of diseases.
- Oncology: Focus on mRNA therapies for various cancer types.
- Inflammatory Diseases: Development of treatments for inflammatory conditions using mRNA technology.
Leadership and Structure
The company is led by a management team with expertise in biotechnology, mRNA technology, and drug development. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- ETX-101 (mRNA Therapeutic for Oncology): An mRNA-based therapeutic designed to target specific cancer cells. Currently in preclinical development, market share information is not yet applicable due to its stage. Competitors developing similar therapies include Moderna (MRNA), BioNTech (BNTX), and CureVac (CVAC).
- ETX-201 (mRNA Therapeutic for Inflammatory Diseases): An mRNA-based therapy aimed at reducing inflammation in specific inflammatory conditions. Preclinical development stage, market share data not yet available. Competitors in the inflammatory disease space include AbbVie (ABBV), Johnson & Johnson (JNJ), and Pfizer (PFE).
Market Dynamics
Industry Overview
The mRNA therapeutics market is experiencing rapid growth, driven by the success of mRNA vaccines and the potential of mRNA technology to treat a wide range of diseases. Key trends include advancements in mRNA delivery, improved stability, and increased investment.
Positioning
Eterna Therapeutics Inc. is positioned as a player in the mRNA therapeutics market, with a focus on oncology and inflammatory diseases. The company's competitive advantage lies in its proprietary mRNA technology and its experienced management team.
Total Addressable Market (TAM)
The global mRNA therapeutics market is projected to reach $50 billion by 2030. Eterna Therapeutics Inc. is positioned to capture a portion of this market through its pipeline of mRNA-based therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA technology platform
- Experienced management team
- Focus on high-growth therapeutic areas
- Strong preclinical pipeline
Weaknesses
- Early stage development
- Limited clinical data
- High cash burn rate
- Dependent on venture capital funding
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancement of pipeline candidates into clinical trials
- Increased investment in mRNA therapeutics
Threats
- Competition from larger biotechnology companies
- Regulatory hurdles
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- CVAC
Competitive Landscape
Eterna Therapeutics Inc. faces significant competition from established biotechnology companies in the mRNA therapeutics market. Its success will depend on its ability to differentiate its technology and advance its pipeline candidates into clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of its preclinical pipeline and securing venture funding.
Future Projections: Future growth is dependent on successful clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing lead candidates into IND-enabling studies and expanding its research and development capabilities.
Summary
Eterna Therapeutics Inc. is a privately held biotechnology company focused on developing mRNA-based therapeutics, primarily in oncology and inflammatory diseases. The company possesses a proprietary mRNA technology platform and an experienced management team, but it is still in an early stage of development. It relies heavily on venture capital funding. Success hinges on advancing their pipeline into clinical trials and potentially partnering with larger pharmaceutical companies amidst stiff competition from established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Venture capital news sources
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eterna Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1992-10-19 | CEO, President & Director Mr. Sanjeev Luther | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.ernexatx.com |
Full time employees 6 | Website https://www.ernexatx.com | ||
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.